Alcohol, Tobacco and Cannabis: What a Canadian Harm Study Really Says
A new Canadian study ranked alcohol and tobacco above cannabis for overall harm, adding urgency to the debate over evidence-based drug policy.
A new Canadian study is challenging familiar assumptions about drug risk. In the researchers' national ranking of overall harm, alcohol came first, tobacco came second and cannabis landed much lower. That result is jarring because alcohol and tobacco are legal, commercially embedded and socially normalized, while marijuana still carries more stigma in much of North America. The paper's central value is its refusal to turn that surprise into a slogan. It does not argue that cannabis is harmless. It argues that the way societies judge drugs often drifts away from the way harm is actually distributed across a population.
That distinction matters right now because debates about marijuana still tend to swing between overcorrection and fear. One side treats cannabis as if legalization settled every safety question. The other still talks as if any relaxation of cannabis laws must invite disorder. The new study, published in the Journal of Psychopharmacology and supported by grants tied to the Canadian Institutes of Health Research, offers a more disciplined frame. Drug harm, the authors argue, is shaped by chemistry, prevalence, patterns of use and the policy environment surrounding a substance. That is a much harder message to weaponize, which is one reason it is worth taking seriously.
A Study That Scrambles Drug Assumptions
The methodology helps explain why this paper deserves attention. A 20-member expert panel from six Canadian provinces evaluated 16 drugs across 16 separate harm criteria. Ten of those criteria measured harms to people who use a substance. Six measured harms to others, including wider family, social and economic damage. Each drug received a 0-100 score for every criterion, and the panel then weighted those harms by importance in a two-day decision conference. This was not a one-note ranking based only on overdose deaths, dependence or criminalization. It was an effort to estimate aggregate burden in Canada as it exists today.
The headline numbers were clear. Alcohol posted the highest cumulative weighted score at 79. Tobacco followed at 45. Nonprescription opioids came next at 33, with cocaine and methamphetamine at 19 each. Cannabis scored 15. Those figures do not mean cannabis is "safe" while alcohol is universally more dangerous to every individual in every setting. They mean that, on a population basis in Canada, alcohol and tobacco create a much larger total burden than cannabis does. That is an important drug policy point, because law often speaks in broad categories while public health has to deal with actual outcomes.
Why Alcohol Came Out on Top
Alcohol's first-place finish was not a statistical fluke. The study found that alcohol ranked first in nine of the 16 harm categories: physical health damage, withdrawal, short- and long-term mental impairment, loss of tangibles, loss of relationships, injury, family and social adversity, and economic cost. That range helps explain why alcohol remains such a difficult public-health problem. Its harms extend far beyond dependence or liver disease. Alcohol reaches into trauma care, domestic instability, workplace productivity, traffic injury and family stress. A substance does not need to look illicit to impose a massive social cost.
The authors also tie alcohol's score to policy failure, not just pharmacology. Their conclusion says the ranking "underscores a failure" to adopt stronger alcohol-harm measures despite the availability of proven interventions. That matches long-standing guidance from the World Health Organization, which says the evidence is strongest for pricing policies and also supports limits on availability and promotion. In plain terms, alcohol's burden is not simply the result of what ethanol does in the body. It is also the result of how available, affordable and culturally protected alcohol remains. Drug policy has consequences long before a substance ever reaches an emergency room.
Tobacco's Persistent Toll
Tobacco's second-place ranking may feel less surprising, yet it says something equally important about normalization. The paper found tobacco ranked first in four categories: mortality, drug-specific physical harm, dependence and environmental damage. That is a brutal profile for a legal consumer product. Tobacco's damage is slower moving than an overdose crisis, which can make it easier for the public to mentally file away. The study does the opposite. It puts tobacco's cumulative burden back in view and treats dependence, disease and environmental consequences as part of the same accounting.
That reading fits the broader medical evidence. The WHO tobacco fact sheet says tobacco kills more than 7 million people each year worldwide, including people exposed to secondhand smoke, and up to half of users who do not quit. Tobacco's legal status has never made it low-risk. It has made the risk familiar. That is part of what this Canadian ranking exposes. A society can become accustomed to a substance's toll without reducing the toll itself. Good drug policy is supposed to interrupt that kind of complacency, not inherit it.
Cannabis Ranked Lower, Not Risk-Free
Cannabis is where careless readers could flatten this study into the wrong lesson. The paper placed cannabis below alcohol, tobacco, opioids, cocaine and methamphetamine overall, which matters. Yet the authors also warn that a low score does not mean a drug causes no harm. For cannabis, the highest weighted harm was organized criminal activity tied to the remaining illegal market. The paper adds that cannabis ranked relatively high for mental harms to users, including dependence, withdrawal and short- and long-term impairment of mental functioning, where it placed third in that combined category. Even in a legal market, cannabis risk does not disappear. It changes shape.
That caution lines up with public-health guidance outside this study. The National Center for Complementary and Integrative Health notes that some people develop cannabis use disorder and that frequent use has been linked to a higher risk of psychosis in people predisposed to it. The CDC says cannabis use is associated with psychosis and other long-lasting mental disorders in some users, while its broader health-effects guidance notes impaired reaction time, decision-making and coordination. Those are not arguments for panic. They are arguments for honesty. Cannabis can be lower on a population harm scale than alcohol and tobacco while still demanding careful screening, product education and risk counseling.
The organized-crime finding deserves a second look because it shows how law and harm interact. The authors note that cannabis's highest weighted harm was linked to the illegal market that persists even after legalization. At the same time, Health Canada reports that 72% of people who used cannabis in the past 12 months in 2024 usually bought it from a legal source, while only 3% reported purchasing from an illegal source. That means legal regulation has shifted a large share of demand away from illicit channels without erasing them. Drug policy rarely produces clean endings. It usually produces trade-offs, incentives and incomplete transitions that still matter for public safety.
What the Findings Mean for Drug Policy
The most important caveat in the paper may be the simplest one: these are population-level harm scores, not a universal measure of how dangerous a drug is for one person. The rankings reflect pharmacology and Canada's current policy context. Prevalence matters. Access matters. Social use patterns matter. Regulation matters. That is why alcohol can outrank substances that may be more acutely dangerous in a narrower clinical sense. It is also why a lower cannabis score does not settle debates about youth use, psychiatric vulnerability, impaired driving or product strength. A serious drug policy conversation has to hold those truths at the same time.
That framework travels well to the United States, even though the Canadian rankings should not be presented as universal. American cannabis policy remains unsettled at the federal level. The Justice Department proposed moving marijuana from Schedule I to Schedule III in 2024, and the DEA said in January 2025 that the rescheduling hearing had been postponed. In other words, the law is still catching up to a rapidly changing market and a more complicated evidence base. That mismatch is one reason marijuana debates in the U.S. still generate more heat than clarity. Drug policy that trails behind evidence leaves patients, clinicians and regulators doing the cleanup.
Arizona offers a practical example of why nuance matters for patients. The state still runs a structured medical marijuana program through ADHS, and its current rules require more than a casual signoff. State rules require a physician diagnosis, a medical record, a recent physical exam, a review of prior records and controlled-substance monitoring information, a discussion of risks and benefits, and a professional opinion that the patient is likely to receive therapeutic or palliative benefit. ADHS reported 82,181 active qualifying patients in November 2025, with 136 operating medical dispensaries as of Dec. 1, 2025. For responsible clinics such as The Marijuana Doctor, that is the real work: separating hype from evidence, protecting patient access and making room for the fact that cannabis can have legitimate medical relevance without becoming consequence-free.
The paradox at the center of this study should make policymakers uncomfortable in the right way. The substances most integrated into ordinary commerce may impose the heaviest aggregate burden. Meanwhile, cannabis remains the subject of sharper stigma, heavier legal confusion and louder cultural panic, even when a contemporary harm ranking places it below alcohol and tobacco. That does not vindicate careless cannabis promotion. It does expose how far public judgment can drift from measured harm. A mature drug policy would take that mismatch seriously, then build rules that reduce harm instead of defending old assumptions. This article is for informational purposes and is not medical advice. Talk with a licensed clinician about your specific situation.
***
Marijuana Doctor is your premier destination for seamless medical marijuana licensing. Our compassionate team guides you with expertise, ensuring a smooth process. Discover the therapeutic benefits in a supportive environment that prioritizes your well-being.
Join a community championing alternative healing methods for a healthier life. Choose Marijuana Doctor for personalized, patient-centered care, and step into a revitalized future.
Follow us on Instagram!
